Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

President Trump has issued more executive orders, aimed at the military, that range from the elimination of DEI policies to ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Blending fantasy and romance is often overdone in the literary world today, but I was pleasantly surprised by the perfect ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...